RecruitingPhase 4Drug trialBEGIN Novel ImagiNG BiomarkersTo determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).